Nutri Co., Ltd.

10 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Jan 2029

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

2 fees due Feb 20 to 22, 2027 · next Feb 20
2 fees due Aug 25 to 27, 2027 · next Aug 25

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

Patent	Title	Status	Expires	Confidence
US 10,568,906	Composition for improving nutritional status, reducing frequency of fever and/or increasing immunocompetence of the elderly In force Term ends Jan 6, 2029 · From the USPTO record	In force	Term ends Jan 6, 2029	From the USPTO record
US 9,511,141	Composition for reducing oxidative stress and/or side effects occurring during cancer chemotherapy or improving nutritional status during cancer chemotherapy In force Term ends Feb 19, 2029 · From the USPTO record	In force	Term ends Feb 19, 2029	From the USPTO record
US 9,872,515	Low-Concentration Nutritional Composition In force Term ends Oct 27, 2029 · High confidence	In force	Term ends Oct 27, 2029	High confidence
US 10,383,893	Composition for reducing the level of glucose, malondialdehyde-modified LDL, homocysteine and/or C-reactive protein in blood In force Term ends Mar 18, 2031 · From the USPTO record	In force	Term ends Mar 18, 2031	From the USPTO record
US 10,806,167	Gelling composition In force Term ends Jul 11, 2036 · From the USPTO record	In force	Term ends Jul 11, 2036	From the USPTO record
US 10,960,034	MRSA infection protective agent In force Term ends Jan 29, 2038 · From the USPTO record	In force	Term ends Jan 29, 2038	From the USPTO record
US 11,911,420	Prophylactic and/or therapeutic agents for Streptococcus pneumoniae infection In force Term ends Feb 6, 2039 · From the USPTO record	In force	Term ends Feb 6, 2039	From the USPTO record
US 12,053,496	Agent for prevention and/or treatment of Pseudomonas aeruginosa infection In force Term ends Apr 18, 2039 · From the USPTO record	In force	Term ends Apr 18, 2039	From the USPTO record
US 11,730,776	Preventive and/or therapeutic agent for clostridium difficile infection In force Term ends Oct 4, 2039 · From the USPTO record	In force	Term ends Oct 4, 2039	From the USPTO record
US 12,616,766	Clostridiodes Difficile Growth Inhibitor In force Term ends Apr 18, 2043 · High confidence	In force	Term ends Apr 18, 2043	High confidence

Also on record, not counted in the 10: 1 lapsed for an unpaid fee · 4 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 abandoned · 2 no status recorded

List them